Kestra Medical Technologies, Ltd.

General Information
Business:	We design, manufacture and sell a wearable cardioverter defibrillator for patients who are at higher risk of cardiac arrest. (Incorporated in Bermuda) We are commercializing our cardiac recovery system platform, an advanced comprehensive system that integrates monitoring, therapeutic treatment, digital health and patient support services into a single unified solution. Our ASSURE WCD is a next generation wearable cardioverter defibrillator (WCD) worn to protect patients who are at an elevated risk of sudden cardiac arrest. Our ASSURE WCD has been worn by more than 17,000 patients since it was commercially launched in August 2022. Our cardiac recovery system – as of Jan. 31, 2025 – is actively prescribed by more than 550 U.S. hospitals. Note: Net loss and revenue are for the 12 months that ended Oct. 31, 2024. (Note: Kestra Medical Technologies, Ltd. filed its S-1 on Feb. 10, 2025, for its IPO, which is expected to raise $100 million. Background: The company submitted confidential IPO documents to the SEC on Aug. 25, 2021.)
Industry:	Medical Equipment & Devices
Employees:	301
Founded:	2014
Contact Information
Address	3933 Lake Washington Blvd NE, Suite 200 Kirkland, Washington 98033
Phone Number	(425) 279-8002
Web Address	https://www.kestramedical.com/
View Prospectus:	Kestra Medical Technologies, Ltd.
Financial Information
Market Cap
Revenues	$45.8 mil (last 12 months)
Net Income	$-84.8 mil (last 12 months)
IPO Profile
Symbol	KMTS
Exchange	NASDAQ
Shares (millions):	0.0
Price range	$0.00 - $0.00
Est. $ Volume	$100.0 mil
Manager / Joint Managers	BofA Securities/Goldman Sachs/Piper Sandler/Wells Fargo Securities/Stifel
CO-Managers
Expected To Trade:
Status:	TBA
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Kestra Medical Technologies, Ltd.

We design, manufacture and sell a wearable cardioverter defibrillator for patients who are at higher risk of cardiac arrest. (Incorporated in Bermuda)

Our ASSURE WCD has been worn by more than 17,000 patients since it was commercially launched in August 2022. Our cardiac recovery system – as of Jan. 31, 2025 – is actively prescribed by more than 550 U.S. hospitals.

Note: Net loss and revenue are for the 12 months that ended Oct. 31, 2024.

(Note: Kestra Medical Technologies, Ltd. filed its S-1 on Feb. 10, 2025, for its IPO, which is expected to raise $100 million. Background: The company submitted confidential IPO documents to the SEC on Aug. 25, 2021.)